AVR 0.99% $15.30 anteris technologies ltd

Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-8

  1. 1,301 Posts.
    Without being experts and trusting the company here, in my opinion this is excellent.

    If it was not worth doing, why continue with it to waste money with so many other projects running?

    Many clinical trials do not get to phase 2a, let alone phase 2b

    I'll leave this one to the experts
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.